Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een fase II-onderzoek naar oppervlakte-elektrische stimulatie voor urine-incontinentie bij mannen die worden behandeld voor prostaatkanker

7 november 2026 bijgewerkt door: National Cancer Institute (NCI)

Background:

Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help.

Objective:

To see if the Elidah device can reduce urinary incontinence after prostate treatment.

Eligibility:

Men aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer.

Design:

Participants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests.

The Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis.

Participants will be given an Elidah device and taught how to use it at home.

They will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks.

Participants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads.

Participants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used.

Participants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment.

Participants will complete 15-minute questionnaires.

Studie Overzicht

Gedetailleerde beschrijving

Background:

  • Urinary incontinence is a common side effect of prostate cancer therapy that can negatively impact the quality of life.
  • Standard treatment includes an initial course of pelvic floor muscle exercises followed by surgical therapy if urinary incontinence persists.
  • Although pelvic floor muscle exercises can be successful in reducing urinary incontinence, compliance with exercises is poor.
  • The Elitone (registered trademark) device was recently cleared by the Food and Drug Administration (FDA) for use in women with stress urinary incontinence. This device provides a surface electrical muscle stimulation device designed to contract the pelvic floor muscles and has been shown to reduce incontinence in women using the product.
  • Recently, the electrode component (GelPad) of the device has been adapted for use in men by the manufacturing company, Elidah. The male version of the device is named the Elidah device.

Objective:

-To describe the efficacy of the Elidah device on male urinary incontinence

Eligibility:

  • Participants must be male.

  • Participants must have a history of urinary incontinence for at least 6 months after prostate cancer treatment.

  • Participants must have at least one of the following types of urinary incontinence:

    • stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities), or on sneezing or coughing;
    • urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.

Design:

  • This is a phase II trial testing the efficacy of the Elidah device in people treated for prostate cancer with stress and/or urge urinary incontinence.
  • Prior to treatment, participants will undergo baseline assessments including 24-hour pad weight testing and questionnaires relating to incontinence and quality of life.
  • Participants will self-administer the Elidah device treatment for 20 minutes per day, 5 days per week during a 6-week period in the at-home environment. Participants will maintain a Daily Log to record usage of the Elidah device, urinary leaks, and use of pads during each week of treatment.
  • Following 6 weeks of therapy, participants will undergo re-evaluation of symptoms and urinary incontinence via questionnaires and testing with the 24-hour pad weight test.

Studietype

Ingrijpend

Inschrijving (Geschat)

41

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Maryland
      • Bethesda, Maryland, Verenigde Staten, 20892
        • Werving
        • National Institutes of Health Clinical Center
        • Contact:
          • National Cancer Institute Referral Office
          • Telefoonnummer: 888-624-1937

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 120 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Mannelijk

Beschrijving

  • INCLUSION CRITERIA:

  • Participants must be male.

  • Participants must have a history of urinary incontinence for at least 6 months after local prostate cancer treatment.

  • Participants must have at least one of the following types of urinary incontinence:

    • stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities) or on sneezing or coughing
    • urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.
  • Participants must have moderate urinary incontinence defined as use of 1-4 pads per day by self-report at screening.

  • Participants must be able to read and write in English.

  • Age >= 18 years.

  • Eastern Cooperative Oncology Group (ECOG) performance status <= 2.

  • Ability to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

  • Change of therapy for prostate cancer planned during the study intervention.
  • History or symptoms of urinary retention (not an exclusion if this occurred before prostatectomy), extra-urethral incontinence, overflow incontinence.
  • Active urinary tract infection (UTI) at screening or history of recurrent urinary tract infections (>= 4 UTIs within the 12 months prior to the study treatment initiation).
  • History of complete denervation of the pelvic floor.
  • Severe obesity (body mass index [BMI] >35).
  • Pelvic pain/painful bladder syndrome.
  • Metal implant in the abdominal or pelvic area.
  • History of chronic cough with ongoing symptoms
  • An implanted cardiac device, history of untreated cardiac arrhythmia, or history of other heart problems.
  • History of epilepsy.
  • History of underlying neurologic/neuromuscular disorder that could contribute to urinary incontinence.
  • Change in medications prescribed for urinary incontinence within 2 weeks prior to the study treatment initiation.
  • Uncontrolled intercurrent illness evaluated by medical history and physical examination or social situations that would limit compliance with study requirements.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: 1/Elidah Device

Elidah device application.

The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To describe the efficacy of the Elidah device treatment on male urinary incontinence
Tijdsspanne: Baseline and within 2 weeks after completing treatment

Percent decrease in 24-hour pad weight after treatment with the Elidah device.

Baseline and within 2 weeks after completing treatment

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To assess the safety of the Elidah device in men with urinary incontinence
Tijdsspanne: 3 week visit and end of treatment visit

Frequency of adverse events among treated participants and reporting the results, by maximum grade of event and type of toxicity noted.

3 week visit and end of treatment visit
To assess alternative measures of efficacy of Elidah device on male urinary incontinence and bother
Tijdsspanne: Baseline and at end of treatment visit

Evaluated by the number of pads and number of leaks before and after treatment. The mean of the percent reduction in the number of pads used per day following treatment will be computed along with 95% confidence intervals.

Baseline and at end of treatment visit
To assess participant-reported outcomes of Elidah device use for male urinary incontinence
Tijdsspanne: Baseline and at end of treatment visit

The proportion of participants for which the I-QoL score improves by 2.5 points or more following six weeks of Elidah device use will be estimated. 95% confidence intervals for this proportion will be constructed.

Baseline and at end of treatment visit
To assess treatment compliance with the Elidah device
Tijdsspanne: 3 week visit and end of treatment visit

A test of binomial proportions will be performed to assess whether the treatment noncompliance rate is above the unacceptability threshold.

3 week visit and end of treatment visit

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Deborah E Citrin, M.D., National Cancer Institute (NCI)

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 februari 2024

Primaire voltooiing (Geschat)

1 december 2027

Studie voltooiing (Geschat)

1 maart 2028

Studieregistratiedata

Eerst ingediend

1 december 2023

Eerst ingediend dat voldeed aan de QC-criteria

1 december 2023

Eerst geplaatst (Werkelijk)

8 december 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 november 2026

Laatste update ingediend die voldeed aan QC-criteria

7 november 2026

Laatst geverifieerd

6 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

All IPD recorded in the medical record will be shared with intramural investigators upon request.

IPD-tijdsbestek voor delen

Clinical data available during the study and indefinitely.

IPD-toegangscriteria voor delen

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren